Medpace Beats Q2 Revenue Estimates

Medpace (NASDAQ:MEDP), a clinical contract research organization, reported strong Q2 2025 earnings, achieving GAAP revenue of $603.3 million and EPS of $3.10, surpassing estimates of $538.8 million and $2.98, respectively. The positive results led management to raise forecasts for the remainder of FY2025, reflecting ongoing operational success and top-line growth.

Want More Context? 🔎

Perspective Meter

LeftCenterRight

?

Bias score hidden

Left-Leaning Coverage

Right-Leaning Coverage

AI Summary

Upgrade to Tidal Access to see the bias score